About this trial
The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent
Disqualifiers
Patients under 18 years of age.
Emergency surgery.
Patients receiving antiplatelet or anticoagulant treatment.
Congenital or acquired platelet function disorders.
Trial population
Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent
Trial design
Cohort
Prospective
Treatments tested in this trial
Thromboelastometry values: EXTEM CT, MCF, α-angle below the lower limit of normal. Measurement obtained after anesthetic induction. - PT, aPTT, fibrinogen, platelet count. - Thrombin generation. -
Diagnostic test* Molecular markers: including Next-Generation Sequencing (Oncomine Comprehensive Assay v3 or Oncomine Precision Assay) when available. * MGMT promoter methylation status.
Treatment groups
Trial outcomes
Primary outcomes
Thromboembolic events
Any newly developed thrombotic event (or acute worsening of a previous one) occurring within: Pulmonary embolism, stroke, venous trombosis
Thromboembolic events
Any thromboembolic events
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fundacion Clinic per a la Recerca Biomédica
Lead sponsor
Hospital Clinic of Barcelona
Sponsor institution
Hospital Clinic of Barcelona
Collaborator